These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 11773290)
1. Efficacy of systemic adjuvant therapy for breast cancer in African-American and Caucasian women. Dignam JJ J Natl Cancer Inst Monogr; 2001; (30):36-43. PubMed ID: 11773290 [TBL] [Abstract][Full Text] [Related]
2. Prognosis among African-American women and white women with lymph node negative breast carcinoma: findings from two randomized clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP). Dignam JJ; Redmond CK; Fisher B; Costantino JP; Edwards BK Cancer; 1997 Jul; 80(1):80-90. PubMed ID: 9210712 [TBL] [Abstract][Full Text] [Related]
3. Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project. Dignam JJ; Colangelo L; Tian W; Jones J; Smith R; Wickerham DL; Wolmark N J Natl Cancer Inst; 1999 Nov; 91(22):1933-40. PubMed ID: 10564677 [TBL] [Abstract][Full Text] [Related]
4. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294 [TBL] [Abstract][Full Text] [Related]
5. Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. McCollum AD; Catalano PJ; Haller DG; Mayer RJ; Macdonald JS; Benson AB; Fuchs CS J Natl Cancer Inst; 2002 Aug; 94(15):1160-7. PubMed ID: 12165641 [TBL] [Abstract][Full Text] [Related]
6. Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer. Dignam JJ; Wieand K; Johnson KA; Raich P; Anderson SJ; Somkin C; Wickerham DL Breast Cancer Res Treat; 2006 Jun; 97(3):245-54. PubMed ID: 16331345 [TBL] [Abstract][Full Text] [Related]
7. Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen. McCaskill-Stevens W; Wilson J; Bryant J; Mamounas E; Garvey L; James J; Cronin W; Wickerham DL J Natl Cancer Inst; 2004 Dec; 96(23):1762-9. PubMed ID: 15572758 [TBL] [Abstract][Full Text] [Related]
8. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. Fisher B; Dignam J; Tan-Chiu E; Anderson S; Fisher ER; Wittliff JL; Wolmark N J Natl Cancer Inst; 2001 Jan; 93(2):112-20. PubMed ID: 11208880 [TBL] [Abstract][Full Text] [Related]
9. Differences in breast cancer prognosis among African-American and Caucasian women. Dignam JJ CA Cancer J Clin; 2000; 50(1):50-64. PubMed ID: 10735015 [TBL] [Abstract][Full Text] [Related]
10. Taxanes for adjuvant treatment of early breast cancer. Willson ML; Burke L; Ferguson T; Ghersi D; Nowak AK; Wilcken N Cochrane Database Syst Rev; 2019 Sep; 9(9):CD004421. PubMed ID: 31476253 [TBL] [Abstract][Full Text] [Related]
11. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group. J Natl Cancer Inst; 1996 Nov; 88(21):1543-9. PubMed ID: 8901852 [TBL] [Abstract][Full Text] [Related]
12. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. Fisher B; Dignam J; Bryant J; DeCillis A; Wickerham DL; Wolmark N; Costantino J; Redmond C; Fisher ER; Bowman DM; DeschĂȘnes L; Dimitrov NV; Margolese RG; Robidoux A; Shibata H; Terz J; Paterson AH; Feldman MI; Farrar W; Evans J; Lickley HL J Natl Cancer Inst; 1996 Nov; 88(21):1529-42. PubMed ID: 8901851 [TBL] [Abstract][Full Text] [Related]
13. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. Fisher B; Jeong JH; Anderson S; Wolmark N J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638 [TBL] [Abstract][Full Text] [Related]
14. Overview of resistance to systemic therapy in patients with breast cancer. Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229 [TBL] [Abstract][Full Text] [Related]
15. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet; 1998 Sep; 352(9132):930-42. PubMed ID: 9752815 [TBL] [Abstract][Full Text] [Related]
16. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. International Breast Cancer Study Group (IBCSG) J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096 [TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401 [TBL] [Abstract][Full Text] [Related]